[en] The aim of this paper was to evaluate the long-term (5 years) efficacy of nasal salmon calcitonin in prevention of trabecular postmenopausal bone loss, which was a follow-up of a previously published study (3 years); a randomized, controlled group comparison. One hundred healthy postmenopausal women were randomly chosen from those (186) having completed the 3 year protocol. The 100 women were allocated to an additional 2 year period (total of 5 years) of treatment with either 500 mg d-1, 5 days week-1 of calcium or the same amount of calcium plus 50 IU d-1, 5 days per week of nasal salmon calcitonin, 87 (87%) women complied with the protocol throughout. The main outcome measures were the bone mineral density of the lumbar spine (1-BMD) (DPA) and biochemical parameters reflecting bone turnover (serum alkaline phosphatases, urinary calcium/creatinine and hydroxyproline/creatinine ratios). The women receiving calcium alone presented a significant decrease in 1-BMD after 6 months [-1.6 (0.5)%] [mean(SEM)] (P < 0.01) and this decrease remained significant after 36 months [-6.1(0.8)%] (P < 0.01) and until the end of the trial [-6.6(1.0)% at t60] (P < 0.01). In women receiving calcium and calcitonin, 1-BMD significantly increased after 36 months [+2(0.7%] (P < 0.01) and 42 months [+2.5(0.7)%] (P < 0.01 and was unchanged at the other times of investigation [+1.1 (1.1)% at t60] (NS). The evolution of BMD in the two groups was highly significantly different (P < 0.001) since the sixth month of the study and remained so until the end of the study.(ABSTRACT TRUNCATED AT 250 WORDS)
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Meurmans, L.
Deroisy, Rita ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Jupsin, Isabelle ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Biquet, I.
Albert, Adelin ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Franchimont, P.
Language :
English
Title :
A 5-Year Controlled Randomized Study of Prevention of Postmenopausal Trabecular Bone Loss with Nasal Salmon Calcitonin and Calcium
Christiansen C, Lindsay R. (1991) Estrogens, bone loss and preservation. Osteoporosis Int 1:7-14.
Copp DH, Cameron EC, Cheney BA, Davidson AGF, Henze KG. (1962) Evidence for calcitonin—A new hormone from the parathyroid that lowers blood calcium. Endocrinology 70:638-649.
Reginster JY, Deroisy R, Albert A, Denis D, Lecart MP, Franchimont P. (1989) Relationship between whole plasma calcitonin levels, calcitonin secretory capacity and plasma levels of esterone in healthy women and postmenopausal osteoporosis. J Clin Invest 83:1073-1077.
Tiegs RD, Body JJ, Barta JM, Heath H. (1985) Plasma calcitonin in primary hyperparathyroidism: failure of C‐cell response to sustained hypercalcaemia. J Clin Endocrinol Metab 63:785-788.
Bijvoet OLM, Van der Sluys‐Veer JD, Jansen AP. (1968) Effects of calcitonin on patients with Paget's disease, thyrotoxicosis or hypercalcaemia. Lancet 1:876-881.
Haddad JG, Birge SJ, Avioli LV. (1970) Effects of prolonged thyrocalcitonin administration on Paget's disease of bone. N Engl J Med 283:549-555.
Buclin T, Randin JP, Jacquet AF (1987) The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif. Tissue Int 41:252-257.
Reginster JY, Denis D, Albert A, Franchimont P. (1987) Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone and Mineral 2:133-140.
Reginster JY, Albert A, Franchimont P. (1985) Salmon calcitonin nasal spray in Paget's disease of bone; preliminary results in five patients. Calcif Tissue Int 37:577-580.
Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP (1987) New modes of administration of salmon calcitonin in Paget's disease. Clin Orthop Rel Res 217:56-71.
Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C. (1991) Dose‐response bioactivity of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 72:344-349.
Reginster JY, Franchimont P. (1985) Side‐effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 3:155-157.
Reginster JY, Denis D, Albert A (1987) 1‐Year controlled randomization trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-1483.
Reginster JY (1991) Calcitonin, effects on bone mass and fracture rates. The American Journal of Medicine 91S5B:19-22.
Reginster JY, Denis D, Deroisy R (1994) Long‐term (3 years) prevention of trabecular postmenopausal bone loss with low dose intermittent nasal salmon calcitonin. J Bone Miner Res 9:69-73.
Krölner B, Porsnielsen S. (1980) Measurement of bone mineral content (BMC) of the lumbar spine. I: Theory and application of a new time‐dimensional dual photon attenuation method. Scandinavian Journal of Clinical and Laboratory Investigation 40:653-663.
Reginster JY, Geusens P, Nijs J, Denis D, Franchimont P, Dequeker J. (1989) In vivo long‐term precision of spinal bone mass measurement by dual photon absorptiometry. Bone Miner 6:225-229.
Trayser KA, Seligson D. (1969) A new kinetic method for enzyme analysis suitable for automation. Clin Chem 15:452-459.
Nordin BEC. (1978) Diagnostic procedure in disorders of calcium metabolism. Clin Endocrinol 8:55-67.
Dixon WJ, Massey FJ. Introduction to Statistical Analysis , 4th ed., Singapore:, MacGraw‐Hill Book Co; 1985, 648.
Zerbe GO. (1979) Randomization analysis of the completely randomized design extended to growth and response curves. Journal of the American Statistical Association 74:215-221.
Reginster JY, Denis D, Deroisy R (1990) Dual photon absorptiometry of lumbar spine in western european (belgian) postmenopausal females: normal range and fracture threshold. Clin Rheum 9:220-224.
Overgaard K, Riis BJ, Christiansen C, Hansen MA. (1989) Effect of salcatonin given intranasally on early postmenopausal bone loss. Br Med J 299:477-479.
Meunier PJ, Gozzo I, Chaumet R (1992) Dose‐effect on bone density and parathyroid function of intranasal salmon calcitonin when administered without calcium in postmenopausal women. J Bone Miner Res 7S1:330.
Stevenson JC, Lees B, Ellerington MC, Whitcroft SIJ, Marsh MS, Whitehead MI. (1992) Postmenopausal osteoporosis: a double‐blind placebo‐controlled study. J Bone Miner Res 7S1:930.
Ribot C, Tremollieres F, Pouilles JM, Chaumet R. (1992) Long‐term effect of nasal calcitonin on vertebral and femoral bone mass in early menopause: Results of a controlled prospective 3‐year study. J Bone Miner Res 7S1:196.
Overgaard K, Hansen MA, Christiansen C. (1992) Effect of intranasal calcitonin on bone mass and bone turnover in early postmenopausal women. A dose‐response study. J Bone Miner Res 7S1:192.
Kanis JA, Gray RE. (1987) Long‐term follow‐up observations on treatment in Paget's disease of bone. Clin Orthop 217:99-125.
Reginster JY, Jeugmans‐Huynen AM, Albert A, Denis D, Franchimont P. (1988) One year treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Miner Res 3:249-252.
Bouizar Z, Rostenne WH, Milhaud G. (1987) Down‐regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc Natl Acad Sci USA 84:5125-5128.
Geusens P, Dequeker J, Verstraeten A, Nijs J. (1986) Age, sex and menopause‐related changes of vertebral and peripheral bone population using dual and single photon absorptiometry and radiogrammetry. J Nucl Med 27:1540-1549.
Dawson‐Hughes B, Dallal GE, Krall EA, Sadowski LJ, Sahyoun N, Tannenbaum S. (1990) A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. New England Journal of Medicine 323:878-883.
Reginster JY, Deroisy R, Sarlat N, Franchimont P. (1990) Relation between calcium intake during different periods of life and bone mineral content at the menopause. Osteoporosis 1990 , Christiansen C, Overgaard K.,. Copenhagn:, Osteopress Publ.; 400-401.
Meunier PJ, Delmas PD, Chaumet‐Riffaud PD (1990) Intranasal salmon calcitonin for prevention of postmenopausal bone loss. A placebo‐controlled study in 109 women. Osteoporosis , Christiansen C, Overgaard K.,. Copenhagen:, Osteopress Publ.; 1861-1867.
Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen J. (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435-442.
